SCHEMBL6358692

SCHEMBL6358692

O=C(NCc1ccco1)c1cccc(Cl)c1Cl

nearest known ligand 0.66

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
HPGD P15428 11/20 0.66
POLB P06746 3/20 0.66
HTT P42858 2/20 0.66
ALDH1A1 P00352 3/20 0.64
SMN1; SMN2 Q16637 2/20 0.64
LMNA P02545 1/20 0.64
MAPT P10636 2/20 0.62
NPSR1 Q6W5P4 1/20 0.59
TDP1 Q9NUW8 1/20 0.58
RAB9A P51151 1/20 0.56
L3MBTL1 Q9Y468 1/20 0.56
TSHR P16473 2/20 0.56
TP53 P04637 1/20 0.56
MAPK1 P28482 1/20 0.56
HSD17B10 Q99714 1/20 0.55
NPC1 O15118 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30639190 0.88 HPGD (0.69) HPGDPOLBHTTALDH1A1SMN1; SMN2
SCHEMBL31092083 0.79 HPGD (1.00) HPGDPOLBHTTALDH1A1SMN1; SMN2
SCHEMBL19420131 0.79 HPGD (0.71) HPGDPOLBHTTALDH1A1SMN1; SMN2
SCHEMBL12172824 0.78 NPSR1 (0.72) HPGDPOLBHTTALDH1A1SMN1; SMN2
SCHEMBL6357294 0.77 L3MBTL1 (0.55) HPGDALDH1A1LMNATDP1RAB9A
SCHEMBL11570780 0.77 TAS1R3 (0.55) HPGDLMNATSHR
SCHEMBL19747003 0.77 HPGD (0.69) HPGDPOLBHTTALDH1A1SMN1; SMN2
SCHEMBL2244634 0.77 HPGD (0.69) HPGDPOLBHTTALDH1A1SMN1; SMN2
SCHEMBL29433997 0.77 HPGD (0.69) HPGDPOLBHTTALDH1A1SMN1; SMN2
SCHEMBL30639163 0.77 HPGD (1.00) HPGDPOLBHTTALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050009812-A1 Remedies for stress diseases comprising mitochondrial benzodiazepine receptor antagonists ONO PHARMACEUTICAL CO., LTD. (JP) 2005-01-13 US claimed
EP-1438973-A1 REMEDIES FOR STRESS DISEASES COMPRISING MITOCHONDRIAL BENZODIAZEPINE RECEPTOR ANTAGONISTS ONO PHARMACEUTICAL CO., LTD. (JP) 2004-07-21 EP claimed
US-20050009812-A1 Remedies for stress diseases comprising mitochondrial benzodiazepine receptor antagonists ONO PHARMACEUTICAL CO., LTD. (JP) 2005-01-13 US disclosed
EP-1438973-A1 REMEDIES FOR STRESS DISEASES COMPRISING MITOCHONDRIAL BENZODIAZEPINE RECEPTOR ANTAGONISTS ONO PHARMACEUTICAL CO., LTD. (JP) 2004-07-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050009812-A1 Remedies for stress diseases comprising mitochondrial benzodiazepine receptor antagonists TFAM, CYP11B2, CYP11B1 HPGD 586/4885POLB 1411/4885HTT 761/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.